+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06102902

Phase 1 Study of ZEN003694 with Cetuximab and Encorafenib for Refractory BRAF V600E Metastatic Colorectal Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-10-30

30

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, optimal dose, and effectiveness of a new drug called ZEN003694 combined with cetuximab and encorafenib in patients who have colorectal cancer that has returned, spread, or not responded to previous treatments. This phase 1 trial studies patients with metastatic colorectal cancer that carries a specific BRAF V600E mutation. ZEN003694 works by blocking BET proteins, which may slow tumor growth, while cetuximab and encorafenib are existing cancer treatments that affect tumor cell survival and immune response. Participants receive ZEN003694 orally once daily for 28 days per cycle, cetuximab through intravenous infusion on days 1 and 15, and encorafenib orally once daily for 28 days each cycle. In the dose-expansion part of the study, encorafenib starts on day 2 of the first cycle and then continues daily thereafter. Treatment cycles repeat every 28 days until the cancer progresses or side effects prevent further treatment. Patients may have biopsies at screening and during the study, as well as imaging scans like CT or MRI and heart function tests through echocardiography or MUGA. Throughout the trial, researchers collect blood samples and monitor patients regularly. After completing treatment, participants are followed every two months to assess outcomes such as the maximum tolerated dose and anti-tumor activity. The study also evaluates how the drugs affect tumor biology, drug levels in the body, and possible resistance mechanisms. Participation continues up to the point of disease progression or unacceptable side effects, with ongoing safety and response monitoring.

CONDITIONS

Brief Title

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here